Oluyemi Okupe Sells 7,950 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock in a transaction on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the transaction, the chief financial officer owned 262,954 shares in the company, valued at $6,216,232.56. This represents a 2.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.96, for a total value of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total value of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total value of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.98, for a total value of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.77, for a total value of $219,088.09.

Hims & Hers Health Trading Up 2.8%

Shares of NYSE:HIMS opened at $23.06 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The business’s fifty day simple moving average is $24.07 and its 200-day simple moving average is $28.28. The company has a market capitalization of $5.26 billion, a PE ratio of -256.21, a P/E/G ratio of 39.59 and a beta of 2.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the prior year, the business posted $0.20 earnings per share. The company’s revenue was up 3.8% compared to the same quarter last year. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the period. Capital World Investors lifted its position in Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after acquiring an additional 223,892 shares during the period. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp lifted its position in Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after acquiring an additional 132,311 shares during the period. Finally, Geode Capital Management LLC lifted its position in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after acquiring an additional 608,950 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its convertible notes offering to $350 million, giving the company more capital for international expansion, a potential Eucalyptus acquisition, and AI/technology investment without relying as heavily on operating cash. Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
• Positive Sentiment: Some commentary sees the company’s Wegovy-related strategy and branded-medication pivot as supporting longer-term growth, suggesting the weight-loss business could remain an important revenue driver. Hims & Hers: Wegovy Deal Fuels Growth
• Neutral Sentiment: Analysts have been asking more questions about the company’s Q1 pivot away from compounded weight-loss products toward branded medications, reflecting uncertainty around margins and near-term execution. 5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call

Analyst Ratings Changes

HIMS has been the subject of a number of recent analyst reports. Bank of America lowered their price objective on Hims & Hers Health from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Tuesday. Citigroup raised their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Truist Financial reissued a “hold” rating and issued a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. UBS Group set a $35.00 price objective on Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $29.37.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.